Skip to main content
Premium Trial:

Request an Annual Quote

Arrayit, DOCRO Sign Deal Aimed at FDA Approval

NEW YORK (GenomeWeb News) – Arrayit said today it has inked a professional services master agreement with Diagnostic Oncology Research Organization to aid it in obtaining approval from the US Food and Drug Administration for its tests.

The agreement will serve as a blueprint for submitting Arrayit's OvaDx presymptomatic ovarian cancer monitoring and screening test, a secondary Parkinson's disease diagnostic test, and other tests in the company's pipeline.

Last week, Arrayit announced a deal with DOCRO to help in the implementation of ISO and CLIA registration and certification for Arrayit's new headquarters in Sunnyvale, Calif. The new labs will be used for the OvaDx and PDx FDA submissions, as well as for patient test sample processing and commercialization upon FDA approval, Arrayit said.

The new labs are scheduled to open Jan. 1, 2014.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.